Thrombolysis in stroke despite contraindications or warnings?

Area of Science:

• Neurology
• Cardiovascular Medicine
• Pharmacology

Background:

• Intravenous thrombolysis with alteplase is a key treatment for acute ischemic stroke.
• Its use is often restricted due to contraindications and warnings derived from clinical trials and expert consensus.
• Limited data exists on alteplase efficacy in patients with these specific contraindications.

Purpose of the Study:

• To evaluate the outcomes of alteplase treatment in acute ischemic stroke patients with and without contraindications.
• To assess the safety and efficacy of alteplase in subgroups of patients with specific contraindications and warnings.

Main Methods:

• Retrospective analysis of a clinical trials archive including 9613 ischemic stroke patients.
• Comparison of outcomes between 2755 alteplase-treated patients and untreated patients.
• Statistical analysis using Cochran-Mantel-Haenszel test and proportional odds logistic regression, adjusted for age and NIH Stroke Score.

Main Results:

• Alteplase treatment was associated with more favorable 90-day outcomes across various subgroups with contraindications.
• Significant benefits observed in patients over 80 years old (OR 1.40), with prior stroke and diabetes (OR 1.50), on antiplatelets (OR 1.42), on anticoagulation (OR 2.20), with high glucose (OR 1.50), and high NIHSS (OR 1.57).
• Confidence intervals generally excluded 1, indicating statistically significant improvements.

Conclusions:

• This study provides evidence supporting the use of alteplase in acute ischemic stroke patients with common contraindications.
• The findings suggest that the benefits of alteplase may outweigh the risks in many patients previously considered ineligible.
• Further research may refine treatment guidelines to include a broader patient population.